Zobrazeno 1 - 10
of 938
pro vyhledávání: '"Relapsed and refractory"'
Autor:
Thomas E. Delea, Qiufei Ma, Glenn S. Kroog, Wenzhen Ge, Aaron Moynahan, Natalia Sabater Anaya, Karen Rodriguez Lorenc, Xue Song
Publikováno v:
Oncology and Therapy, Vol 12, Iss 3, Pp 565-583 (2024)
Abstract Introduction Treatment of multiple myeloma (MM) has been transformed by novel therapies, including CD38 monoclonal antibodies (mAbs), immunomodulatory drugs (IMiDs), and proteasome inhibitors (PIs), resulting in increasing numbers of patient
Externí odkaz:
https://doaj.org/article/dc949fc5b05f41759a3c90d8afe88775
Autor:
Xubo Gong, Lianjun Zhang, Xin He, Jing Yang, Xiang Li, Weiwei Liu, Bin Zhang, Zhihua Tao, Wenbin Qian
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-4 (2024)
Abstract Natural killer (NK) cell-based therapies have made great progress in treating both hematological and solid tumors. Their unique mechanism of action does not rely on antigen presentation to recognize and eliminate tumor cells, making them a p
Externí odkaz:
https://doaj.org/article/5aca4f5190264219b91e460327579337
Publikováno v:
Health Economics Review, Vol 14, Iss 1, Pp 1-10 (2024)
Abstract Background Relapsed or refractory classic Hodgkin lymphoma (RRcHL) associates with poor prognosis and heavy disease burden to patients. This study evaluated the cost-effectiveness of brentuximab vedotin (BV) in comparison to conventional che
Externí odkaz:
https://doaj.org/article/565d114d5e3f47c6b9480d93b196dc4d
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
BackgroundChimeric antigen receptor (CAR) T-cell therapy (CAR-T therapy) has demonstrated significant efficacy in the ZUMA-2 study. After regulatory approvals, several clinical trials and real-world studies on CAR-T therapy for relapsed or refractory
Externí odkaz:
https://doaj.org/article/77ee455c538846b6a30c8e7306381ee7
Autor:
Jie Xu, Bai-Yan Wang, Shan-He Yu, Shi-Jun Chen, Shuang-Shuang Yang, Rui Liu, Li-Juan Chen, Jian Hou, Zhu Chen, Wan-Hong Zhao, Ai-Li He, Jian-Qing Mi, Sai-Juan Chen
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-13 (2024)
Abstract Background The autologous anti–B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy LCAR-B38M has been approved for the treatment of relapsed and refractory multiple myeloma in many countries across the world und
Externí odkaz:
https://doaj.org/article/bd5fe093d29e44bdad66104c6ea27c5c
Autor:
Winfried Alsdorf, Joris Diels, Francesca Ghilotti, Joao Mendes, Teresa Hernando, Patricia Cost, Jordan M Schecter, Nikoletta Lendvai, Nitin Patel, Ana Triguero, Margherita Ursi
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 13, Iss 9 (2024)
Aim: The phase III randomized controlled trial (RCT) CARTITUDE-4 (NCT04181827) demonstrated superiority of CARVYKTI (ciltacabtagene autoleucel; cilta-cel) over daratumumab, pomalidomide and dexamethasone (DPd) and pomalidomide, bortezomib and dexam
Externí odkaz:
https://doaj.org/article/68a2d3ea79dc4be895e782945880ef4d
Autor:
Adnan Danish, Alexandra Della Pia, Lindsay Fogel, Hassan Alkhatatneh, Charles Zhao, Tony Varughese, Karine A. Al Feghali, Lauren Pascual, Brittany Sinclaire, Michael Marafelias, Joshua Zenreich, Yen-Hong Kuo, Tatyana A. Feldman, Yi Zhang, Andre H. Goy, Andrew Ip, Scott D. Rowley
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Background and purposeThe aim of this study was to determine the prevalence of patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) meeting high-risk criteria for early relapse after CD19 CAR T-cell therapy (CART) who have disease en
Externí odkaz:
https://doaj.org/article/8182706d74724ca58c0b8faeef2b98b0
Autor:
Wenjiao Tang, Yan Li, Li Zhang, Xushu Zhong, Qiushi Liang, Yuhuan Zheng, Yuzhang Liu, Yafei Wang, Xunqiang Wang, Yun Zeng, Baijun Fang, Li Zheng, Ting Niu
Publikováno v:
Cancer Medicine, Vol 13, Iss 14, Pp n/a-n/a (2024)
Abstract Objective TQB3602 is a novel orally bioavailable proteasome inhibitor. This study is the first‐in‐human phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of TQB3602 in relapsed/refrac
Externí odkaz:
https://doaj.org/article/79c01800aa18488eb3d8ccb5d79f76f4
Autor:
Kanwal Asghar, Maryam Zafar, Eva Holland, Ali Bin Abduljabbar, Sara A. Albagoush, Noureen Asghar, Akshat Sood, Jalal M. Dufani, Joseph Thirumalaredy, Bradley DeVrieze, Abubakar Tauseef, Muhammad Husnain
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionInconsistent results observed in recent phase III trials assessing chimeric antigenic receptor T (CAR-T) cell therapy as a second-line treatment compared to standard of care (SOC) in patients with relapsed/refractory diffuse large B-cell
Externí odkaz:
https://doaj.org/article/5ca47676a1184f45ba516d15dd1a524a
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary approach in the treatment of lymphoma. This review article provides an overview of the four FDA-approved CAR T-cell products for aggressive B-cell lymphoma, including diffuse large B-c
Externí odkaz:
https://doaj.org/article/bacde77b5e434402aa3b72d843d89947